Massimo Andreoni1, Sergio Babudieri2, Savino Bruno3, Massimo Colombo4, Anna L Zignego5, Vito Di Marco6, Giovanni Di Perri7, Carlo F Perno8, Massimo Puoti8, Gloria Taliani9, Erica Villa10, Antonio Craxì11. 1. Infectious Diseases, Polyclinic of Rome Tor Vergata, Rome, Italy. 2. Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. 3. Humanitas University and Humanitas Research Hospital, Rozzano, Milan, Italy. 4. Humanitas Clinical and Research Center, Humanitas Research Hospital, Rozzano, Milan, Italy. 5. Department of Experimental and Clinical Medicine, Interdepartmental Centre MASVE, University of Florence, Florence, Italy. 6. Sezione di Gastroenterologia e Epatologia, DiBiMIS, University of Palermo, Palermo, Italy. 7. Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy. 8. Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy. 9. Infectious and Tropical Diseases Unit, Umberto I Hospital-"Sapienza" University, Rome, Italy. 10. Department of Internal Medicine, Gastroenterology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy. 11. Gastroenterology and Liver Unit, DiBiMIS, University of Palermo, Palermo, Italy. antonio.craxi@unipa.it.
Abstract
BACKGROUND: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. METHODS: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. RESULTS AND CONCLUSIONS: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.
BACKGROUND: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. METHODS: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. RESULTS AND CONCLUSIONS: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.
Authors: Steven Harper; John A McCauley; Michael T Rudd; Marco Ferrara; Marcello DiFilippo; Benedetta Crescenzi; Uwe Koch; Alessia Petrocchi; M Katharine Holloway; John W Butcher; Joseph J Romano; Kimberly J Bush; Kevin F Gilbert; Charles J McIntyre; Kevin T Nguyen; Emanuela Nizi; Steven S Carroll; Steven W Ludmerer; Christine Burlein; Jillian M DiMuzio; Donald J Graham; Carolyn M McHale; Mark W Stahlhut; David B Olsen; Edith Monteagudo; Simona Cianetti; Claudio Giuliano; Vincenzo Pucci; Nicole Trainor; Christine M Fandozzi; Michael Rowley; Paul J Coleman; Joseph P Vacca; Vincenzo Summa; Nigel J Liverton Journal: ACS Med Chem Lett Date: 2012-03-02 Impact factor: 4.345
Authors: Edward Gane; Fred Poordad; Stanley Wang; Armen Asatryan; Paul Y Kwo; Jacob Lalezari; David L Wyles; Tarek Hassanein; Humberto Aguilar; Benedict Maliakkal; Ran Liu; Chih-Wei Lin; Teresa I Ng; Jens Kort; Federico J Mensa Journal: Gastroenterology Date: 2016-07-25 Impact factor: 22.682
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Maria Buti; Stuart C Gordon; Eli Zuckerman; Eric Lawitz; Jose L Calleja; Harald Hofer; Christopher Gilbert; John Palcza; Anita Y M Howe; Mark J DiNubile; Michael N Robertson; Janice Wahl; Eliav Barr; Xavier Forns Journal: Clin Infect Dis Date: 2015-09-14 Impact factor: 20.999
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245